Arctic Bioscience AS (DE:9TD) has released an update.
Sofie H. Valderhaug, associated with Arctic Bioscience’s CEO, has purchased 4,000 shares of the company at NOK 10.50 each, now holding the same number of shares. The biotech firm focuses on developing pharmaceuticals and nutraceuticals, including a promising new drug, HRO350, aimed at treating psoriasis.
For further insights into DE:9TD stock, check out TipRanks’ Stock Analysis page.
